Trial in Adult Subjects With Spinocerebellar Ataxia
Status:
Active, not recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140
milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with
spinocerebellar ataxia (SCA).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceuticals, Inc.